长春高新：子公司获GenSci098项目7000万美元首笔付款

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has signed an exclusive licensing agreement with Yarrow for the GenSci098 injection project, which will enhance the company's cash reserves and support its pipeline development and international strategy [1] Group 1 - The exclusive licensing agreement was signed on December 15, 2025, granting Yarrow global exclusive development rights for GenSci098 injection outside of Greater China [1] - The first payment of $70 million is expected to be received on January 14, 2026, although the actual amount will be subject to taxes and fees [1] - GenSci098 injection is a self-developed product by Jinsai Pharmaceutical, which has already been approved for clinical trials in both China and the United States [1]